Testosterone therapy and prostate carcinoma

  title={Testosterone therapy and prostate carcinoma},
  author={Ernani Lu{\'i}s Rhoden and M{\'a}rcio Augusto Averbeck},
  journal={Current Urology Reports},
Hypogonadism is a clinical and biochemical syndrome associated with a range of disease states that has significant effects on morbidity and mortality and also affects quality of life. Because of the increase in life expectancy and prostate carcinoma (PCa) survival, a significant increase in the number of men with hypogonadism who have undergone presumably curative treatment of PCa is anticipated. Despite the widespread belief regarding contraindication of testosterone administration to men with… Expand
Differing levels of testosterone and the prostate: a physiological interplay
This Review will re-examine classic androgen research and reflect on whether testosterone actually stimulates prostatic cellular growth and progression in a 'threshold' or a 'dose–response' manner, as well as discuss the influence of testosterone on prostate cells in the hypogonadal and eugonadal states. Expand
Association between Testosterone and Prostate Cancer among SudanesePatients in Khartoum State
Background: Prostate is a compound tubuloalveolar exocrine gland of the male reproductive system in most mammals. It considers differ among species anatomically chemically and physiologically.Expand
Cardiometabolic Complications after Androgen Deprivation Therapy in a Man with Prostate Cancer: Effects of 3 Years Intermittent Testosterone Supplementation
This case provides support that once regression of PCa growth is attained, T supplementation may be administered in well differentiated PCa, especially if IAB is not successful in reverting iatrogenic hypogonadism and its associated cardiac and metabolic complications. Expand
Combined tests of prostate specific antigen and testosterone will improve diagnosis and monitoring the progression of prostate cancer
The in vitro data demonstrated that cultured LNCaP cells ceased to produce PSA after androgen withdrawal and resumed PSA production after androgens was re-added, indicating that the androgen is a key factor controlling the production of PSA. Expand
Prostate Cancer: Biology, Incidence, Detection Methods, Treatment Methods, and Vaccines.
  • R. Bartzatt
  • Medicine, Biology
  • Current topics in medicinal chemistry
  • 2020
Prostate cancer is the most common malignancy in American men, accounting for more than 29% of all diagnosed cancers and about 13% ofall cancer deaths, and a shortened course of hormonal therapy with docetaxel following radical prostatectomy for high-risk prostate cancer has been shown to be both safe and feasible. Expand
The Role of Testosterone in the Etiology and Treatment of Obesity, the Metabolic Syndrome, and Diabetes Mellitus Type 2
Testosterone plays a significant role in obesity, glucose homeostasis, and lipid metabolism, and Administration of testosterone to hypogonadal men reverses part of the unfavorable risk profile for the development of diabetes and atherosclerosis. Expand
Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro
It is concluded that physiologically normal levels of androgen inhibit the proliferation of PCa cells in vitro, however, at very low levels androgens are essential for initial growth ofPCa cells. Expand
Delayed Penile Rehabilitation Post Radical Prostatectomy (CME)
John is a 54-year-old married male who underwent an uneventful radical retropubic robotic prostatectomy 12 months prior to presentation and his continence improved within weeks of the surgery and is now complete. Expand
Menthol evokes Ca2+ signals and induces oxidative stress independently of the presence of TRPM8 (menthol) receptor in cancer cells
Results based on pharmacological tools point to an involvement of the purinergic pathway in menthol-evoked Ca2+ responses in breast and prostate cancer cell lines, indicating a TRPM8-independent signaling pathway. Expand


Androgen replacement in men undergoing treatment for prostate cancer.
There is no convincing evidence that the normalization of testosterone serum levels in men with low but no castrate levels is deleterious, and the available evidence suggests that TRT can be cautiously considered in selected hypogonadal men treated with curative intent for PCa and without evidence of active disease. Expand
Testosterone and prostate cancer: an historical perspective on a modern myth.
There is not now-nor has there ever been-a scientific basis for the belief that testosterone (T) causes prostate cancer (pCA) growth, and this historical perspective reveals that this modern myth is a modern myth. Expand
Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement.
It is demonstrated that the level of PSA was not significantly changed after 1 year of testosterone replacement therapy in patients with hypogonadism associated with ED, and there was no significant association between PSA level and the duration of testosterone Replacement therapy in the study population. Expand
Testosterone replacement therapy after primary treatment for prostate cancer.
Hypogonadal patients with a history of prostate cancer had no PSA recurrence and had statistically significant improvements in TT and hypog onadal symptoms after TRT, suggesting that in highly select patients after RRP TRT can be administered carefully and with benefit to hypogonadism. Expand
Testosterone replacement therapy following radical prostatectomy.
TRT is effective in improving testosterone levels, without increasing PSA values, in hypogonadal men who have undergone RP and also to evaluate the impact of pathologic Gleason grade on ultimate PSAvalues. Expand
Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review
A comprehensive search of MEDLINE, EMBASE and other resources was conducted to identify articles that highlight occurrences of prostate cancer in men receiving testosterone therapy for hypogonadism treatment, finding that testosterone therapy did not have a consistent effect on prostate-specific antigen levels. Expand
Prostate cancer after exogenous testosterone treatment for impotence.
A man treated with exogenous testosterone for impotence who subsequently was diagnosed with prostate cancer and reported on a man who had prostate cancer after testosterone replacement therapy. Expand
Response of men with advanced prostatic carcinoma to exogenous administration of testosterone
The authors conclude that the response to exogenous testosterone is variable and unpredictable and in certain patients in relapse may be of appreciable palliative value. Expand
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Preliminary data suggest that in aging men with late-onset hypogonadism, 6 months of TRT normalizes serum androgens levels but appears to have little effect on prostate tissue androgen levels and cellular functions. Expand
Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy
The objective of this study was to assess the risk of biochemical failure with TRT after treatment of early prostate cancer with permanent transperineal brachytherapy with or without external beam therapy in patients with low serum levels of testosterone and clinical symptoms of hypogonadism. Expand